http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Oct 2026 16:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VEEVA+SYSTEMS+INC+++++++++For%3A+Oct+14++Filed+by%3A+Faddis+Jonathan/27198299.html si-local-file:///var/storage/secattach/20261016/27198299.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++VEEVA+SYSTEMS+INC+++++++++For%3A+Oct+14++Filed+by%3A+Faddis+Jonathan/27198299.html Fri, 16 Oct 2026 16:32:00 -0400 VEEV http://www.streetinsider.com/SEC+Filings/Form++144++++++++VEEVA+SYSTEMS+INC++++++++++++++++++++++Filed+by%3A+Schwenger+Thomas+D./27193714.html si-local-file:///var/storage/secattach/20261015/27193714.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++VEEVA+SYSTEMS+INC++++++++++++++++++++++Filed+by%3A+Schwenger+Thomas+D./27193714.html Thu, 15 Oct 2026 16:25:00 -0400 VEEV http://www.streetinsider.com/SEC+Filings/Form++144++++++++VEEVA+SYSTEMS+INC++++++++++++++++++++++Filed+by%3A+Schwenger+Thomas+D./27193626.html si-local-file:///var/storage/secattach/20261015/27193626.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++VEEVA+SYSTEMS+INC++++++++++++++++++++++Filed+by%3A+Schwenger+Thomas+D./27193626.html Thu, 15 Oct 2026 16:18:00 -0400 VEEV http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Reiterates+Outperform+Rating+on+Veeva+Systems+%28VEEV%29/27188588.html <p>Oppenheimer analyst Ken Wong reiterated an Outperform rating and $325.00 price target on Veeva Systems (NYSE: VEEV).</p><p>The analyst comments "Recent investor conversations have largely centered on potentially seeing further R&D deceleration implied by the outlook. Our catch-up with VEEV suggests R&D growth is tracking to plan. Management originally framed the growth dynamic as transitioning from the "old guard" of R&D products to the smaller, but faster growing "new guard." Demand remains broad-based across R&D, with no obvious pull-forward driving 1H outperformance. Veeva's increased guidance was driven by execution and improved visibility. Business consulting is a durable services growth driver while http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Reiterates+Outperform+Rating+on+Veeva+Systems+%28VEEV%29/27188588.html Thu, 15 Oct 2026 05:00:33 -0400 VEEV http://www.streetinsider.com/Press+Releases/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization</li><li style="margin-bottom:6pt; text-align:justify;">Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled</li><li style="margin-bottom:6pt; text-align:justify;">Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing<br></br><br></br> </li></ul> <p align="justify">GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with http://www.streetinsider.com/Press+Releases/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html Thu, 15 Oct 2026 03:30:00 -0400 APMD VEEV VTVT http://www.streetinsider.com/Globe+Newswire/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization</li><li style="margin-bottom:6pt; text-align:justify;">Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled</li><li style="margin-bottom:6pt; text-align:justify;">Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing<br></br><br></br> </li></ul> <p align="justify">GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with http://www.streetinsider.com/Globe+Newswire/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html Thu, 15 Oct 2026 03:30:00 -0400 APMD VEEV VTVT http://www.streetinsider.com/Press+Releases/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization</li><li style="margin-bottom:6pt; text-align:justify;">Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled</li><li style="margin-bottom:6pt; text-align:justify;">Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing<br></br><br></br> </li></ul> <p align="justify">GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with http://www.streetinsider.com/Press+Releases/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html Thu, 15 Oct 2026 03:30:00 -0400 APMD VEEV VTVT http://www.streetinsider.com/Globe+Newswire/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization</li><li style="margin-bottom:6pt; text-align:justify;">Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled</li><li style="margin-bottom:6pt; text-align:justify;">Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing<br></br><br></br> </li></ul> <p align="justify">GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with http://www.streetinsider.com/Globe+Newswire/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html Thu, 15 Oct 2026 03:30:00 -0400 APMD VEEV VTVT http://www.streetinsider.com/Press+Releases/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization</li><li style="margin-bottom:6pt; text-align:justify;">Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled</li><li style="margin-bottom:6pt; text-align:justify;">Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing<br></br><br></br> </li></ul> <p align="justify">GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with http://www.streetinsider.com/Press+Releases/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html Thu, 15 Oct 2026 03:30:00 -0400 APMD VEEV VTVT http://www.streetinsider.com/Globe+Newswire/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization</li><li style="margin-bottom:6pt; text-align:justify;">Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled</li><li style="margin-bottom:6pt; text-align:justify;">Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing<br></br><br></br> </li></ul> <p align="justify">GENEVA, AMSTERDAM and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with http://www.streetinsider.com/Globe+Newswire/iOnctura+appoints+Paul+Sekhri+as+Chair+of+its+Board+of+Directors/27188498.html Thu, 15 Oct 2026 03:30:00 -0400 APMD VEEV VTVT http://www.streetinsider.com/SEC+Filings/Form++144++++++++VEEVA+SYSTEMS+INC++++++++++++++++++++++Filed+by%3A+Schwenger+Thomas+D./27187178.html si-local-file:///var/storage/secattach/20261014/27187178.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++VEEVA+SYSTEMS+INC++++++++++++++++++++++Filed+by%3A+Schwenger+Thomas+D./27187178.html Wed, 14 Oct 2026 16:07:00 -0400 VEEV http://www.streetinsider.com/Press+Releases/Veeva+to+Host+Virtual+Investor+Day+on+November+5%2C+2026/27187112.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.pleton" idsrc="xmltag.org" >PLEASANTON, Calif.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.veeva.com/" target="_blank" rel="nofollow"><span value="NYSE:VEEV" idsrc="xmltag.org" >Veeva Systems</span></a> (NYSE: VEEV) will host its investor day virtually on <chron>Thursday, November 5, 2026</chron>. The event will begin at <chron>1:30 p.m. PT</chron> and will conclude at approximately <chron>3:30 p.m. PT</chron>.</p> <p><span value="NYSE:VEEV" idsrc="xmltag.org" >Veeva</span> will broadcast the presentations live on the company's investor relations website, <a target="_blank" href="http://ir.veeva.com/" target="_blank" http://www.streetinsider.com/Press+Releases/Veeva+to+Host+Virtual+Investor+Day+on+November+5%2C+2026/27187112.html Wed, 14 Oct 2026 16:05:00 -0400 VEEV http://www.streetinsider.com/PRNewswire/Veeva+to+Host+Virtual+Investor+Day+on+November+5%2C+2026/27187112.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.pleton" idsrc="xmltag.org" >PLEASANTON, Calif.</location></span>, <span class="legendSpanClass"><chron>Oct. 14, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.veeva.com/" target="_blank" rel="nofollow"><span value="NYSE:VEEV" idsrc="xmltag.org" >Veeva Systems</span></a> (NYSE: VEEV) will host its investor day virtually on <chron>Thursday, November 5, 2026</chron>. The event will begin at <chron>1:30 p.m. PT</chron> and will conclude at approximately <chron>3:30 p.m. PT</chron>.</p> <p><span value="NYSE:VEEV" idsrc="xmltag.org" >Veeva</span> will broadcast the presentations live on the company's investor relations website, <a target="_blank" href="http://ir.veeva.com/" target="_blank" http://www.streetinsider.com/PRNewswire/Veeva+to+Host+Virtual+Investor+Day+on+November+5%2C+2026/27187112.html Wed, 14 Oct 2026 16:05:00 -0400 VEEV http://www.streetinsider.com/SEC+Filings/Form++144++++++++VEEVA+SYSTEMS+INC++++++++++++++++++++++Filed+by%3A+Faddis+Jonathan/27187085.html si-local-file:///var/storage/secattach/20261014/27187085.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++VEEVA+SYSTEMS+INC++++++++++++++++++++++Filed+by%3A+Faddis+Jonathan/27187085.html Wed, 14 Oct 2026 16:03:00 -0400 VEEV http://www.streetinsider.com/Corporate+News/IQVIA+expands+Veeva+partnership+for+clinical+operations+tools/27176952.html <p>IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced an expansion of their existing partnership, with IQVIA selecting Veeva's CTMS, eTMF, Study Startup, and Site Connect applications as enterprise standard tools across its clinical development studies, according to a press release.</p><p>The move builds on a previously announced electronic data capture (EDC) partnership between the two companies. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack.</p><p>Richard Staub, president of Research and Development Solutions at IQVIA, said the integration gives clinical teams "a more connected way to work, built on frictionless integration of http://www.streetinsider.com/Corporate+News/IQVIA+expands+Veeva+partnership+for+clinical+operations+tools/27176952.html Tue, 13 Oct 2026 07:06:21 -0400 IQV VEEV http://www.streetinsider.com/Hot+Corp.+News/IQVIA+expands+Veeva+partnership+for+clinical+operations+tools/27176952.html <p>IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced an expansion of their existing partnership, with IQVIA selecting Veeva's CTMS, eTMF, Study Startup, and Site Connect applications as enterprise standard tools across its clinical development studies, according to a press release.</p><p>The move builds on a previously announced electronic data capture (EDC) partnership between the two companies. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack.</p><p>Richard Staub, president of Research and Development Solutions at IQVIA, said the integration gives clinical teams "a more connected way to work, built on frictionless integration of http://www.streetinsider.com/Hot+Corp.+News/IQVIA+expands+Veeva+partnership+for+clinical+operations+tools/27176952.html Tue, 13 Oct 2026 07:06:21 -0400 IQV VEEV http://www.streetinsider.com/Corporate+News/IQVIA+expands+Veeva+partnership+for+clinical+operations+tools/27176952.html <p>IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced an expansion of their existing partnership, with IQVIA selecting Veeva's CTMS, eTMF, Study Startup, and Site Connect applications as enterprise standard tools across its clinical development studies, according to a press release.</p><p>The move builds on a previously announced electronic data capture (EDC) partnership between the two companies. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack.</p><p>Richard Staub, president of Research and Development Solutions at IQVIA, said the integration gives clinical teams "a more connected way to work, built on frictionless integration of http://www.streetinsider.com/Corporate+News/IQVIA+expands+Veeva+partnership+for+clinical+operations+tools/27176952.html Tue, 13 Oct 2026 07:06:21 -0400 IQV VEEV http://www.streetinsider.com/Hot+Corp.+News/IQVIA+expands+Veeva+partnership+for+clinical+operations+tools/27176952.html <p>IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced an expansion of their existing partnership, with IQVIA selecting Veeva's CTMS, eTMF, Study Startup, and Site Connect applications as enterprise standard tools across its clinical development studies, according to a press release.</p><p>The move builds on a previously announced electronic data capture (EDC) partnership between the two companies. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack.</p><p>Richard Staub, president of Research and Development Solutions at IQVIA, said the integration gives clinical teams "a more connected way to work, built on frictionless integration of http://www.streetinsider.com/Hot+Corp.+News/IQVIA+expands+Veeva+partnership+for+clinical+operations+tools/27176952.html Tue, 13 Oct 2026 07:06:21 -0400 IQV VEEV http://www.streetinsider.com/Press+Releases/IQVIA+Selects+Veeva+Clinical+Operations+Applications/27176920.html <p> RESEARCH TRIANGLE PARK, N.C. &amp; PLEASANTON, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iqvia.com%2F&amp;esheet=54620663&amp;newsitemid=20261013187834&amp;lan=en-US&amp;anchor=IQVIA&amp;index=1&amp;md5=6e6fe5c756528b5b15d877747970f376" shape="rect">IQVIA</a> (NYSE:IQV) and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veeva.com%2F&amp;esheet=54620663&amp;newsitemid=20261013187834&amp;lan=en-US&amp;anchor=Veeva+Systems&amp;index=2&amp;md5=54de3fb16a1b6f12196857283cdac970" shape="rect">Veeva Systems</a> (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20261013187834/en/" rel="nofollow">https://www.businesswire.com/news/home/20261013187834/en/</a></p><p> Together, IQVIA and Veeva bring best-in-class capabilities to clinical research to help customers increase trial speed and efficiency, strengthen site centricity, and http://www.streetinsider.com/Press+Releases/IQVIA+Selects+Veeva+Clinical+Operations+Applications/27176920.html Tue, 13 Oct 2026 07:03:00 -0400 IQV VEEV http://www.streetinsider.com/Business+Wire/IQVIA+Selects+Veeva+Clinical+Operations+Applications/27176920.html <p> RESEARCH TRIANGLE PARK, N.C. &amp; PLEASANTON, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iqvia.com%2F&amp;esheet=54620663&amp;newsitemid=20261013187834&amp;lan=en-US&amp;anchor=IQVIA&amp;index=1&amp;md5=6e6fe5c756528b5b15d877747970f376" shape="rect">IQVIA</a> (NYSE:IQV) and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veeva.com%2F&amp;esheet=54620663&amp;newsitemid=20261013187834&amp;lan=en-US&amp;anchor=Veeva+Systems&amp;index=2&amp;md5=54de3fb16a1b6f12196857283cdac970" shape="rect">Veeva Systems</a> (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20261013187834/en/" rel="nofollow">https://www.businesswire.com/news/home/20261013187834/en/</a></p><p> Together, IQVIA and Veeva bring best-in-class capabilities to clinical research to help customers increase trial speed and efficiency, strengthen site centricity, and http://www.streetinsider.com/Business+Wire/IQVIA+Selects+Veeva+Clinical+Operations+Applications/27176920.html Tue, 13 Oct 2026 07:03:00 -0400 IQV VEEV http://www.streetinsider.com/Press+Releases/IQVIA+Selects+Veeva+Clinical+Operations+Applications/27176920.html <p> RESEARCH TRIANGLE PARK, N.C. &amp; PLEASANTON, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iqvia.com%2F&amp;esheet=54620663&amp;newsitemid=20261013187834&amp;lan=en-US&amp;anchor=IQVIA&amp;index=1&amp;md5=6e6fe5c756528b5b15d877747970f376" shape="rect">IQVIA</a> (NYSE:IQV) and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veeva.com%2F&amp;esheet=54620663&amp;newsitemid=20261013187834&amp;lan=en-US&amp;anchor=Veeva+Systems&amp;index=2&amp;md5=54de3fb16a1b6f12196857283cdac970" shape="rect">Veeva Systems</a> (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20261013187834/en/" rel="nofollow">https://www.businesswire.com/news/home/20261013187834/en/</a></p><p> Together, IQVIA and Veeva bring best-in-class capabilities to clinical research to help customers increase trial speed and efficiency, strengthen site centricity, and http://www.streetinsider.com/Press+Releases/IQVIA+Selects+Veeva+Clinical+Operations+Applications/27176920.html Tue, 13 Oct 2026 07:03:00 -0400 IQV VEEV http://www.streetinsider.com/Business+Wire/IQVIA+Selects+Veeva+Clinical+Operations+Applications/27176920.html <p> RESEARCH TRIANGLE PARK, N.C. &amp; PLEASANTON, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iqvia.com%2F&amp;esheet=54620663&amp;newsitemid=20261013187834&amp;lan=en-US&amp;anchor=IQVIA&amp;index=1&amp;md5=6e6fe5c756528b5b15d877747970f376" shape="rect">IQVIA</a> (NYSE:IQV) and <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veeva.com%2F&amp;esheet=54620663&amp;newsitemid=20261013187834&amp;lan=en-US&amp;anchor=Veeva+Systems&amp;index=2&amp;md5=54de3fb16a1b6f12196857283cdac970" shape="rect">Veeva Systems</a> (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20261013187834/en/" rel="nofollow">https://www.businesswire.com/news/home/20261013187834/en/</a></p><p> Together, IQVIA and Veeva bring best-in-class capabilities to clinical research to help customers increase trial speed and efficiency, strengthen site centricity, and http://www.streetinsider.com/Business+Wire/IQVIA+Selects+Veeva+Clinical+Operations+Applications/27176920.html Tue, 13 Oct 2026 07:03:00 -0400 IQV VEEV http://www.streetinsider.com/Press+Releases/Veeva+Summit+to+Showcase+AI+Innovations+and+the+Leaders+Transforming+R%26amp%3BD+and+Quality/27163481.html <div class="xn-content"> <p class="prntac"><i>Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing</i></p> <p><span class="legendSpanClass"><location value="LU/us.ca.pleton" idsrc="xmltag.org" >PLEASANTON, Calif.</location></span>, <span class="legendSpanClass"><chron>Oct. 8, 2026</chron></span> /PRNewswire/ -- At <a target="_blank" href="https://www.veeva.com/events/rd-summit/" target="_blank" rel="nofollow">Veeva R&amp;D and Quality Summit</a> on <chron>October 20-21</chron> in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location>, <a target="_blank" href="https://www.veeva.com/" target="_blank" rel="nofollow"><span value="NYSE:VEEV" idsrc="xmltag.org" >Veeva Systems</span></a> (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, http://www.streetinsider.com/Press+Releases/Veeva+Summit+to+Showcase+AI+Innovations+and+the+Leaders+Transforming+R%26amp%3BD+and+Quality/27163481.html Thu, 08 Oct 2026 07:03:00 -0400 VEEV http://www.streetinsider.com/PRNewswire/Veeva+Summit+to+Showcase+AI+Innovations+and+the+Leaders+Transforming+R%26amp%3BD+and+Quality/27163481.html <div class="xn-content"> <p class="prntac"><i>Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing</i></p> <p><span class="legendSpanClass"><location value="LU/us.ca.pleton" idsrc="xmltag.org" >PLEASANTON, Calif.</location></span>, <span class="legendSpanClass"><chron>Oct. 8, 2026</chron></span> /PRNewswire/ -- At <a target="_blank" href="https://www.veeva.com/events/rd-summit/" target="_blank" rel="nofollow">Veeva R&amp;D and Quality Summit</a> on <chron>October 20-21</chron> in <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston</location>, <a target="_blank" href="https://www.veeva.com/" target="_blank" rel="nofollow"><span value="NYSE:VEEV" idsrc="xmltag.org" >Veeva Systems</span></a> (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, http://www.streetinsider.com/PRNewswire/Veeva+Summit+to+Showcase+AI+Innovations+and+the+Leaders+Transforming+R%26amp%3BD+and+Quality/27163481.html Thu, 08 Oct 2026 07:03:00 -0400 VEEV http://www.streetinsider.com/Corporate+News/More+than+175+biotechs+adopt+Veeva+Basics+for+drug+development+ops/27157875.html <p>Veeva Systems (NYSE: VEEV) announced that more than 175 emerging biotechnology companies have adopted its Veeva Basics platform, a suite of pre-configured and pre-validated applications covering clinical, regulatory, quality, medical, and commercial functions.</p><p>According to the company's press release, biotechs are deploying the applications within weeks, with the platform built to scale as companies grow from startup to commercialization. The applications run on Veeva's Vault Platform.</p><p>One feature highlighted in the announcement is Veeva Submissions Publishing Basics, which allows regulatory teams to bring submission publishing in-house rather than relying on outside vendors. The tool is aimed at companies preparing to file their http://www.streetinsider.com/Corporate+News/More+than+175+biotechs+adopt+Veeva+Basics+for+drug+development+ops/27157875.html Wed, 07 Oct 2026 07:05:42 -0400 GPCR VEEV